NEW YORK (GenomeWeb) — The Mayo Clinic has launched a targeted-sequencing panel test, called CANCP, through its Department of Laboratory Medicine and Pathology's CLIA lab to guide targeted treatment for patients with solid tumors.

The test, which analyzes hotspot regions of 50 genes associated with sensitivity to a variety of genomically targeted cancer therapies, will be available to all patients at the clinic with solid tumors, as well as outside patients and physicians through the Mayo Medical Laboratories.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.